drugset
drugset / Trial / NCT03123289

Novel Gallium 68 Citrate in Orthopedic Infections

NCT03123289 ↗

Phase 2 Terminated 1 enrolled Rutgers, The State University of New Jersey
Non-randomizedCrossoverOpen-labelDiagnostic

Summary

In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68Gallium citrate and 18F-FDG in subjects with failed hip or knee prosthesis. Both 68Gallium-citrate and 18F-FDG scans, done within 24-48 hours from each other, will be performed within 4 weeks before surgical evaluation/revision of the hardware.

Timeline

Start
2017-03-06
Primary completion
2020-10-14
Completion
2020-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent 370 mbq Intravenous
Subject 68Ga-citrate Diagnostic / imaging agent 185 mbq Intravenous

Indications

No indication recorded.